Sentence examples for multiple preclinical models from inspiring English sources

In this report, we provide data that demonstrate the effectiveness of anti-VEGF therapy as a modulator of immune cell infiltration, and intra-tumoral and serum cytokine levels in multiple preclinical models of breast cancer.

These therapies provide significant survival benefits, but more importantly synergize with anti-VEGF therapies in multiple preclinical models.

The inhibition of autophagy augments the efficacy of anticancer agents in a variety of tumour in multiple preclinical models.

Historically, mGlu1 NAMs have shown efficacy in multiple preclinical models that predict antipsychotic efficacy in WT mice and rats.

Hence, TRAIL exerts a selective antitumor activity without eliciting systemic toxicity in multiple preclinical models, and is considered to be a prime candidate for prostate cancer therapy [ 3].

Modulation of granulocyte apoptosis either by inhibition of kinases, by ligation of death receptors, or by use of lipid mediators have demonstrated efficacy in multiple preclinical models of inflammatory disease (10, 11, 13, 15).

Although further mechanistic investigation into the regulation of metastasis by HOTAIR is necessary, the observed prometastatic activity of HOTAIR in multiple preclinical model systems supports HOTAIR to be a potential target for melanoma metastasis therapy.

Olesoxime (TRO19622) was identified as a potential treatment of SMA based on its beneficial effects in multiple preclinical neurodegeneration models.

The compound also showed excellent efficacy in multiple preclinical animal models related to psychiatric disorders, particularly schizophrenia.

Notably, we found that Uncl-Sema3E not only inhibited endothelial cells in culture, but its ectopic expression strongly impaired tumour angiogenesis and tumour growth in multiple preclinical tumour models in mice, either spontaneously or generated by cancer cell transplantation.

We demonstrated in multiple preclinical mouse models that the systemic delivery of Uncl-Sema3E induces tumour shrinkage (comparable to VEGF inhibitors or possibly better) and concomitantly prevents cancer cell invasion and metastatic spreading.